Venture Capital

Marking its 10th year, The Odlum Brown Forum Pitch awarded three innovative women-led startups and raised a record $1.52 million to tackle the funding gap.

A new five-year partnership seeks to bridge the gap between clinical insight and investment, speeding up patient access to new medical technologies.

TRexBio has dosed the first patient in a new trial for its novel drug, TRB-061, which aims to rebalance the immune system to treat atopic dermatitis.

With its new Observability 3.0 platform, OpenObserve introduces an autonomous AI SRE agent to unify monitoring and slash costs, ending 'data diets'.

A new device gets the CE Mark to modernize a 60-year-old cardiac test, promising clearer, faster diagnosis of shunts linked to stroke in millions.

A new brain-inspired chip placed inside the tire promises to give autonomous vehicles a real-time sense of road grip, preventing accidents before they happen.

Anduin launches Instant Extraction, using AI to digitize offline investor documents, aiming to end the era of manual data entry for fund managers.

Chinese robotics firm KaiTu Technology debuts its AI-powered forklifts and AMRs in Silicon Valley, signaling a new era of global competition in automation.

Imviva Biotech's new CAR-T therapy shows potential for durable remission in lupus, moving advanced cell treatments beyond cancer to autoimmune disease.

Investment firm Malar Group backs wellness startup Attaboy Labs, betting on clinical science over marketing hype in the booming supplement industry.

A new conversational AI tool promises to act as an expert whisperer for R&D teams, unlocking siloed materials data and accelerating innovation.

Berlin-based Tacalyx is advancing its lead drug, TCX-201, to the clinic, targeting a novel class of antigens once thought impossible to drug.

A new stem cell therapy promises a one-time cure for hemophilia A, and the FDA is clearing the path. Could lifelong, costly infusions become a memory?

The Defense Logistics Agency has awarded a landmark $50M contract to Corsha to rapidly deploy identity-based Zero Trust security across its critical OT systems.

As DLH Holdings prepares its Q2 results, investors watch to see if it can navigate contract losses and prove its mettle in the federal tech space.

With patient enrollment accelerating for its novel lung fibrosis drug, LTI-03, Rein Therapeutics signals progress in a field desperate for new options.

Seattle startup CounterX Therapeutics to present its novel overdose prevention drug at a top investor event, signaling new hope in the fentanyl crisis.

Oral care leader quip and skincare giant Glowbar partner, signaling a major shift toward simplified, habit-driven wellness. What does this mean for you?

Snap CEO Evan Spiegel will headline Augmented World Expo, unveiling new tools from subsidiary Specs Inc. and charting a course for human-empowered spatial AI.

The largest deal in epigenetic testing sees TruDiagnostic's parent buy Dr. David Sinclair's Tally Health, aiming to make personalized longevity mainstream.